Compare Humana Inc (HUM) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Innodata Inc — how do they compare? Humana Inc trades at $406.5 (market cap $47.81B), while Innodata Inc trades at $63.4 (market cap $2.03B). The key difference: Humana Inc is far larger — about 23.6× Innodata Inc's market cap, and Humana Inc pays a 0.89% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| HUM | INOD | |
|---|---|---|
Market Cap | $47.81B | $2.03B |
Sector | Health | Technology |
52-Week High | $409.42 | $121.50 |
52-Week Low | $163.67 | $34.45 |
Enterprise Value | $56.85B | $1.91B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
INOD trades at $62.08, up 2.09% today, showing strong momentum despite a bearish technical signal. The company demonstrates robust fundamentals with revenue growth from $252M in 2025 to $283M projected for 2026, and net income margins improving to 13.86%. Recent earnings beats and positive AI-driven news highlight growing demand for its engineering R&D services. Technical indicators show mixed signals with RSI suggesting oversold conditions but moving averages indicating bearish pressure.
Outlook remains positive with 60% analyst buy ratings and a $130 consensus price target representing 109% upside. Key opportunities include AI market expansion and customer diversification, while risks center on high valuation multiples (P/E 54.29) and customer concentration. The stock's recent 33% pullback may present a buying opportunity for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
